2024/08/30 22:00:00 | |
---|---|
Price | |
495.89 USD | |
Difference | 0.51% (2.54) |
ISIN | US92532F1003 |
Symbol | VRTX |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 115,515 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 489.83 USD (100) |
Ask (Ask size) | 505.00 USD (100) |
Open | 495.67 USD |
High | 500.25 USD |
Low | 492.29 USD |
Close (prev. day) | 493.35 USD |
VWAP | 496.081028 USD |
Volume (pcs) | 1,809,680 |
Trading volume | 897,826,981.28 |
Number of trades | 28,379 |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/08/12 |
![]() |
Global Equity Ratings |
![]() |
2024/07/24 |
![]() |
Global Equity Ratings |
![]() |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/08/30 22:00:00 | |
---|---|
Price | |
495.89 USD | |
Difference | 0.51% (2.54) |
ISIN | US92532F1003 |
Symbol | VRTX |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 115,515 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 489.83 USD (100) |
Ask (Ask size) | 505.00 USD (100) |
Open | 495.67 USD |
High | 500.25 USD |
Low | 492.29 USD |
Close (prev. day) | 493.35 USD |
VWAP | 496.081028 USD |
Volume (pcs) | 1,809,680 |
Trading volume | 897,826,981.28 |
Number of trades | 28,379 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | +15.64% | +40.12% | +166.24% |
Perf (abs.) | +60.85 | +128.85 | +280.98 |
Beta | 0.43 | 0.56 | 0.60 |
Volatility | 18.52 | 22.82 | 26.49 |
Ø price 5 days | Ø volume 5 days (pcs.) | 488.38 USD (1,079,720) |
Ø price 30 days | Ø volume 30 days (pcs.) | 484.34 USD (1,152,007) |
Ø price 100 days | Ø volume 100 days (pcs.) | 457.95 USD (1,165,658) |
Ø price 250 days | Ø volume 250 days (pcs.) | 417.41 USD (1,236,514) |
YTD High | date | 510.64 USD (2024/08/01) |
YTD Low | date | 391.01 USD (2024/04/18) |
52 Weeks High | date | 510.64 USD (2024/08/01) |
52 Weeks Low | date | 340.83 USD (2023/09/06) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/08/30 | 17:35 | 446.30 EUR | 0.02 | 5 |
Vienna Stock Exchange | 2024/08/30 | 17:32 | 446.20 EUR | 0.00 | 5 |
Tradegate | 2024/08/30 | 22:26 | 448.50 EUR | 0.10 | 20 |
Stuttgart | 2024/08/30 | 17:03 | 446.40 EUR | 0.02 | 5 |
Nasdaq | 2024/08/30 | 22:00 | 495.89 USD | 897.83 | 28,379 |
Munich | 2024/08/30 | 17:27 | 445.45 EUR | 0.00 | 3 |
London Stock Exchange | 2024/08/30 | 17:31 | 493.40 USD | 0.01 | 5 |
Hanover | 2024/08/30 | 17:25 | 446.00 EUR | 0.00 | 4 |
Hamburg | 2024/08/30 | 17:25 | 446.05 EUR | 0.00 | 3 |
Frankfurt | 2024/08/30 | 08:00 | 444.45 EUR | 0.00 | 2 |
Euronext Milan MTF Trading After Hours | 2024/07/04 | 18:14 | 448.30 EUR | 0.00 | 1 |
Euronext Milan MTF Global Equity Market | 2024/08/30 | 17:44 | 447.25 EUR | 0.00 | 1 |
Duesseldorf | 2024/08/30 | 19:30 | 448.25 EUR | 0.00 | 5 |
Berlin | 2024/08/30 | 08:08 | 444.95 EUR | 0.00 | 3 |
VERTEX PHARMACEUTICALS INC. |
- - |
50 Northern Avenue - 02210 Boston |
Telefon: +1-617-341-6100 |
Fax: + |
E-mail: mediainfo@vrtx.com |
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. |
Jeffrey Leiden | Chairman of Board of Directors |
Alan Garber | Member of Board of Directors |
Jennifer Schneider | Member of Board of Directors |
Sangeeta Bhatia | Member of Board of Directors |
Bruce Sachs | Member of Board of Directors |
Diana McKenzie | Member of Board of Directors |
Lloyd Carney | Member of Board of Directors |
Michel Lagarde | Member of Board of Directors |
Nancy Thornberry | Member of Board of Directors |
Suketu Upadhyay | Member of Board of Directors |
Reshma Kewalramani | Chairman of Managing Board |
David Altshuler | Member of Executive Committee |
Amit K. Sachdev | Member of Executive Committee |
Bastiano Sanna | Member of Executive Committee |
Carmen Bozic | Member of Executive Committee |
Charles F. Wagner | Member of Executive Committee |
E. Morrey Atkinson | Member of Executive Committee |
Jonathan Biller | Member of Executive Committee |
Nia Tatsis | Member of Executive Committee |
Stuart A. Arbuckle | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer